Introduction
============

Biliary drainage under endoscopic retrograde cholangiopancreatography (ERCP) guidance is the gold standard technique for bile duct obstruction. In patients who have multiple biliary obstructions and complications such as hepatic hilar obstruction (HBO), deployment of multiple stents is needed. A recent randomized trial showed that bilateral biliary drainage resulted in fewer reinterventions and favorable stent patency compared with unilateral biliary drainage [@JR1573-1] . For bilateral stent deployment, use of both a side-by-side (SBS) and a stent-in-stent (SIS) technique have been reported [@JR1573-2] [@JR1573-3] [@JR1573-4] [@JR1573-5] [@JR1573-6] . In the case of high-grade HBO, which sometimes requires placement of three or more stents, the SIS technique may be challenging. The SBS technique is also challenging because of the limited diameter of the common bile duct. Recently, a novel technique combining SIS and SBS (hybrid technique) has been reported for such cases [@JR1573-7] . This novel technique may have applications for HBO because it reduces the number of times the stent mesh has to be passed. Recently, a new UCSEMS has become available in Japan. We herein report technical tips for hybrid metal stent deployment for high-grade HBO using this novel UCSEMS in a pilot study.

Patients and methods
====================

Patients with complicated HBO were enrolled between November 2018 and January 2019. According to the Bismuth-Corlette classification, only patients with consecutive type IIIa were included. All patients were histologically diagnosed as having unresectable HBO using endoscopic ultrasound-guided fine-needle aspiration.

For this study protocol, bilateral stent deployment in the left and anterior bile ducts were performed first If infected bile juice was aspirated from the posterior bile duct, deployment of triple stents was attempted. In this study, patients who underwent triple stent deployment using the hybrid technique were enrolled.

This study was approved by the ethics committee of our hospital, and patients provided written, informed consent for all procedures associated with it.

. Technical tips for hybrid metal stent deployment
--------------------------------------------------

###### 

  **Video 1**  According to cholangiography, high-grade hepatic hilar obstruction is seen. Guidewire deployments are performed in the left, anterior, and posterior bile duct. Then, newly uncovered self-expandable metal stent deployments are simultaneously performed in the left and posterior bile ducts. Finally, after the guidewire is inserted into the anterior bile duct through the mesh of metal stent in the posterior bile duct, stent deployment is performed in the anterior bile duct.

[Fig. 1](#FI1573-1){ref-type="fig"} shows the new UCSEMS (ZEOSTENT V: Zeon Medical Inc., Tokyo, Japan). This stent is a laser-cutting type UCSEMS ( [Fig. 1a](#FI1573-1){ref-type="fig"} ), available in diameters from 6 mm to 10 mm and lengths from 6 cm to 10 cm. The stent delivery system is 5.4 Fr ( [Fig. 1b](#FI1573-1){ref-type="fig"} ), and the discrepancy between the guidewire and the top of the stent delivery system is strongly reduced ( [Fig. 1c](#FI1573-1){ref-type="fig"} ). Therefore, stent insertion into the biliary tract across the stricture site or through the mesh technique may be easy.

![ A newly UCSEMS (ZEOSTENT V: Zeon Medical Inc., Tokyo, Japan). **a** This stent is laser cutting type UCSEMS. **b** The stent delivery system is only 5.4 Fr, and **c** discrepancy between the guidewire and top of stent delivery system is strongly reduced.](10-1055-a-0998-7847-i1573ei1){#FI1573-1}

[Video 1](#ME1573-1){ref-type="media"} shows technical tips for the hybrid metal stent deployment technique. A JF260V duodenoscope (Olympus Optical, Tokyo, Japan) was advanced into the ampulla of Vater, followed by biliary cannulation with a standard ERCP catheter (MTW Endoskopie, Düsseldorf, Germany). If the main pancreatic duct was to be cannulated, a 0.025-inch guidewire was inserted for the double guidewire technique. After achieving biliary cannulation, contrast medium was injected into the biliary tract, and the site of obstruction was evaluated. Frist, the 0.025-inch guidewire (VisiGlide 1; Olympus Medical Systems, Tokyo, Japan) was deployed into the left, anterior, and posterior bile ducts. During this procedure, the ERCP catheter was inserted into the posterior bile duct and bile juice was aspirated. If the bile juice was infected, deployment of triple stents was attempted. Then, stent delivery systems were simultaneously inserted into the left and right bile ducts using two devices in a one-channel method ( [Fig. 2a](#FI1573-2){ref-type="fig"} ) and stent deployment was simultaneously performed. After the guidewire was removed from the left bile duct, the guidewire in the posterior bile duct was advanced into the anterior bile duct through the mesh of the UCSEMS in the posterior bile duct ( [Fig. 2b](#FI1573-2){ref-type="fig"} ). Next, the stent delivery system was inserted into the anterior bile duct over the guidewire ( [Fig. 2c](#FI1573-2){ref-type="fig"} ), and stent deployment was successfully performed without any adverse events (AE) ( [Fig.2d](#FI1573-2){ref-type="fig"} ).

![Stent delivery systems is inserted into the left and posterior bile ducts using two devices in one channel method. **b** Stent deployments are simultaneously performed. **c** The stent delivery system is inserted into the anterior bile duct over the guidewire. **d** Stent deployment is successfully performed.](10-1055-a-0998-7847-i1573ei2){#FI1573-2}

Definitions
-----------

Technical success was defined as deployment of three stents using hybrid metal stent deployment in a single session. Clinical success was defined as a reduction in bilirubin values to normal (\< 1.3 mg/dL) or less than half of the pre-drainage value within 1e month. Procedural duration was defined as the amount of elapsed time between scope insertion and stent deployment. Stent dysfunction was determined based on recurrent obstructive jaundice, clinical symptoms suggestive of acute cholangitis, and dilation of the biliary tracts on computed tomography. Stent patency was measured from stent deployment to stent dysfunction or the patient's death. AEs were graded according to the severity grading system of the American Society for Gastrointestinal Endoscopy lexicon [@JR1573-8] .

Results
=======

[Table 1](#TB1573-1){ref-type="table"} shows patients characteristics. Hybrid metal stent deployment using the novel UCSEMS was attempted in seven patients (median age, 77 years; range, 74 -- 92 years; male, n = 4). HBO disease was mainly cholangiocarcinoma (n = 6). Unresectability largely was a result of advanced stage of cholangiocarcinoma (n = 5). Two patients had complications from another advanced carcinoma (lung cancer, n = 1; uterine cancer, n = 1). In this study, a 8-mm diameter and 8-cm-long UCSEMS was used in all patients. Technical success was obtained in all patients, although mild post-ERCP pancreatitis was seen in one patient, which was successfully treated by conservative treatment. In this study, after stent deployment in the left and posterior bile ducts, a third stent insertion could be performed without dilation of the mesh in the metal stent in the posterior bile duct. Mean procedure time was 33.3 minutes (range, 27 -- 43). Clinical success was obtained in six patients. On patient in whom clinical success was not achieved received best supportive care. After stent deployment, chemotherapy was attempted in four patients. In this study, stent dysfunction was seen in only one patient. That individual had cholangitis, and because of poor performance status, we treated conservatively. Mean survival in this study was 118 days (range 48 to 198), and duration of stent patency up to patient death was 115 days (range 48 to 177).

###### Patient characteristics.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **No**   Age/gender   Diagnosis of HBO   Reason for unresectability   Chemotherapy   Technical success   Clinical success   Procedure time (min)   Patency (days)   Dysfunction (revision)   Survival (days)
  -------- ------------ ------------------ ---------------------------- -------------- ------------------- ------------------ ---------------------- ---------------- ------------------------ -----------------
  1        77/M         CCC                Advanced cancer              Done           Yes                 Yes                32                     122              --                       122

  2        92/F         CCC                Advanced cancer              Done           Yes                 Yes                39                     109              --                       109

  3        88/M         CCC                Advanced LC                  None           Yes                 None               31                      48              --                        48

  4        70/F         CCC                Advanced cancer              Done           Yes                 Yes                43                     160              --                       160

  5        69/M         CCC                Advanced cancer              Done           Yes                 Yes                27                     177              Cholangitis\             198
                                                                                                                                                                      (none)                   

  6        81/F         CCC                Advanced UC                  None           Yes                 Yes                29                      88              --                        88

  7        74/M         GC                 Advanced GC                  Done           Yes                 Yes                32                     101              --                       101
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HBO, hepatic bile duct obstruction; CCC, cholangiocarcinoma; GC: gastric cancer; OC, uterine cancer; LC, lung cancer

Discussion
==========

Deployment of three UCSEMS is technically challenging. Although the SBS technique is technically easy, deployment of three UCSEMS via SBS may be difficult due to the limited diameter of the biliary tract. Therefore, when three or more UCSEMS are to be deployed, the SIS technique is usually attempted. Kamamoto et al. described the effectiveness of three-branched UCSEMS deployment using the SIS technique in nine consecutive patients [@JR1573-9] . In that study, technical success was obtained in all patients, however, procedure time was relatively long (mean 74.3 min, range, 45 -- 127) compared with our results. Lee et al. [@JR1573-10] evaluated technical feasibility and efficacy of deployment of a third metal stent to create triple SIS placement in patients with bilateral SIS configuration. Among 156 patients, after stent deployment using the SIS technique, early clinical failure or uncontrolled cholangitis were seen in 21 patients. In addition, insertion of the third stent failed in three patients. Therefore, if guidewire or stent delivery insertion failed after one or two stents deployment using the SIS technique, focal cholangitis of another area can occur. Compared with deployment of a third stent using the SIS technique, the hybrid metal stent technique using the novel UCSEMS has several advantages. First, because the SBS technique is included, deployment of two stents can be performed. Second, compared with the SIS technique, guidewire or stent insertion into the third area is easy. In addition, the shaft of the novel UCSEMS is only 5.4 Fr, and its top is extremely tapered, making stent insertion through the mesh easy compared with experience with the previously described UCSEMS. In addition, we were able to insert all stent delivery systems through the stricture site without pre-dilation. This may be one of the benefits of this stent. However, reintervention may be challenging. In this study, although stent dysfunction was seen in one patient and treated conservatively, reintervention after hybrid stent deployment was not evaluated. Regarding stent patency, the duration of our results is shorter than in with previous reports. This may be based on the short survival in our patient population. Therefore, stent patency after hybrid stent deployment could not be evaluated. These facts are the limitations of this study. In addition, our study has critical limitations such as the small case series, retrospective nature, and single-arm design. A prospective comparison study is needed to verify our results.

Conclusion
==========

In conclusion, the hybrid metal stent placement technique appears to be useful with the new UCSEMS because of its fine-gauge stent delivery system.
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